Abstract The influence of CYP2D6 genotype on the efficacy of tamoxifen (Tam) has been extensively analyzed in early breast cancer with conflicting results. However, there is only scarce data regarding this potential influence in advanced breast cancer (ABC). We hypothesize that Tam is more effective in patients with a functional CYP2D6 allele than in patients with impaired CYP2D6 activity. ABC patients with prior or ongoing palliative Tam treatment (20 mg/d) were eligible. Genomic DNA was extracted from blood (n = 51) and formalin-fixed, paraffin-embedded tissue (n = 43). CYP2D6*2, *3, *4, *5, *6, *10, *17, *29, *41, CYP2D6 duplication and multiplication were determined in blood and CYP2D6*4 in tissue samples. Primary endpoint was progression free survival (PFS); secondary endpoints included clinical benefit (CB), and overall survival (OS). The clinical charts were retrospectively analyzed regarding survival and treatment effects. Genotyping was performed blinded and clinical data were analyzed separately. 94 patients were identified with a median age of 59 years (29-90 years). In 6 patients genotyping did not show conclusive results, therefore these patients were excluded from further analysis. Genotyping results were as follows: 1.1 % ultrarapid, 84.1 % extensive, 3.4 % intermediate, and 11.4 % poor metabolizers. Patients without any fully functional allele (IM/IM, IM/PM, PM/PM) had a significant shorter PFS and OS compared to patients with at least one functional allele (EM/EM, EM/IM, EM/PM) (PFS: p = 0.017; HR = 2.19; 95 % CI 1.15-4.18; OS: p = 0.028; HR = 2.79; 95 % CI 1.12-6.99). The CB rate was 73 % for EM-group and 38.5 % for IM ? PM-group (p = 0.019). Our results show a significant influence of the CYP2D6 genotype on the efficacy of Tam in the treatment of ABC. In contrast to the adjuvant setting, the evidence in the palliative setting is congruent. CYP2D6 testing in ABC should be considered.
Introduction
The influence of CYP2D6 metabolism on the efficacy of tamoxifen (Tam) has been the subject of extensive research, and is intensively discussed at present. Tam is used in the therapy of endocrine receptor-positive breast cancer in adjuvant and palliative settings, as well as in prevention for high risk pre-and post-menopausal women [1] . Five years adjuvant Tam treatment approximately halves the annual odds of recurrence and reduces the mortality rate by a third [2] . However, a considerable percentage of patients with endocrine receptor-positive tumors do not profit in any way from Tam treatment or even develop Tam-induced adverse events. Reasons for this variability in response are multifactorial, though, drug interactions and genetic factors affecting the metabolizing enzymes involved in the activation and excretion of Tam could be significant contributing factors [3] .
Tam is considered a prodrug and has itself a relatively low affinity to estrogen receptors [4] . The metabolic pathway of Tam is catalyzed by several cytochrome P450 (CYP) enzymes [4] . Endoxifen, the most abundant active metabolite with more potent antiestrogenic effects than Tam [5, 6] , is primarily produced by the biotransformation of Tam to N-desmethyl-tamoxifen catalyzed by CYP3A4/5 and further metabolized to 4-hydroxy-N-desmethyltamoxifen (endoxifen) exclusively via CYP2D6 [4, 7] . CYP2D6, however, is a highly polymorphic gene with more than 100 known variant alleles, many of which lead to altered CYP2D6 enzyme activity [7] [8] [9] . Based on in vitro and in vivo studies, CYP2D6 variant alleles can be differentiated into four subgroups according to their predicted variant enzyme activity: (1) alleles with increased activity (e.g. CYP2D6*1xN, *2xN), (2) functional or wildtype (wt) alleles (e.g. CYP2D6*1, *2), (3) alleles with reduced activity (e.g. CYP2D6*10, *41), and (4) null alleles, i.e., without any enzyme activity (e.g. CYP2D6*3, *4, *5, and *6) [8] . The CYP2D6*3, *4, *5, and *6 alleles account for more than 80 % of the latter [10] , and in Caucasians the most common null allele is CYP2D6*4 with a frequency of 20 % [11] . Based on the combination of these different alleles, four metabolic phenotypes can be distinguished: Ultrarapid (UM), extensive (EM), intermediate (IM), and poor metabolizers (PM). Of note, metabolic ratio concentrations of CYP2D6 substrates can vary sixfold or more between patients with a PM/PM and an EM/EM phenotype [12] . Approximately 5-10 % of all Caucasians are PMs [13] .
The influence of CYP2D6 metabolism on the efficacy of Tam and its clinical significance has been the subject of extensive research. Several studies have shown that plasma concentrations of the potent metabolite endoxifen are associated with the CYP2D6 genotype [7, 9] . To the best of our knowledge up to now only two groups analyzed data on advanced breast cancer (ABC) [14, 15] , and both found an influence of CYP2D6 genotype on Tam efficacy. In contrast, studies concerning the adjuvant and prevention settings showed highly contradictory results. While in some studies, a significant effect with worse outcome parameters for patients with a decreased CYP2D6 metabolism [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] was established, others did not find any significant influence [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] .
The aim of the current study was therefore, to further test the role of CYP2D6 genotype in Tam-treated ABC patients.
Materials and methods

Patients and study design
Patients with ABC and immunohistochemical verified positive hormone receptor status (ER and/or PR) treated prior or ongoing with Tam (20 mg per day for[30 days) in a palliative setting were eligible for this analysis. Comedication with CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion, duloxetine, terbinafine, amiodarone, cimetidine, citalopram, and sertraline) during the time that Tam was used for metastatic disease was an exclusion criterion. The last follow-up was between May and August 2012. The study protocol was approved by the ethic committee of our hospital and all participants gave informed consent. Patient charts were retrospectively analyzed according to Tam treatment effects, progression-free survival, overall survival, treatments before Tam therapy, number and location of metastatic sites, and comedication. Participants were observed at the beginning of the first Tam prescription for metastatic disease until their death or until the end of the study period.
The primary efficacy endpoint was progression-free survival (PFS); secondary endpoints included clinical benefit (CB) rate, duration of CB, and overall survival (OS). PFS was defined as the time from initiation of Tam treatment for ABC to objective tumor progression or death. OS was defined as the time from initiation of Tam treatment for ABC until death from any cause. The response evaluation criteria in solid tumors (RECIST) guidelines were used to assess the response to therapy. CB was defined as confirmed absence of progression for at least 6 months. Genotyping data were pseudonymized. The results of the clinical analysis and the genotyping results were documented in different tables in order to allow for blinded analysis.
Genetic analysis of single nucleotide polymorphisms
Extraction of genomic DNA from 2 ml peripheral blood (n = 51) or from formalin-fixed, paraffin-embedded (FFPE) tissues (n = 43) was done using the QIAamp DNA blood kit or the QIAamp DNA FFPE tissue kit, respectively (QIAGEN, Hilden, Germany), following the manufacturer 0 s instructions. Yield and purity were determined using a NanoDrop ND-1000 spectrophotometer. All DNA samples were analyzed for the single nucleotide polymorphism (SNP) 1846G [ A (rs3892097), characteristic for CYP2D6*4. As the genomic DNA obtained from the formalin-fixed, paraffin-embedded tissues was found to be substantially fragmented (data not shown), genotyping for the following genetic variations was only possible for the blood samples:
, and gene duplication or multiplications. Genotyping for these variants in blood samples allowed the identification of the most common alleles of CYP2D6: wild-type (wt) allele CYP2D6*1 and variant alleles CYP2 D6*2 (rs16947, rs1135840), CYP2D6*3 (rs35742686), CYP2D6*4 (rs3892097), CYP2D6*5, CYP2D6*6 (rs5030 655), CYP2D6*10 (rs28371706), CYP2D6*17 (rs28371706, rs16947), CYP2D6*29 (rs59421388) and CYP2D6*41 (rs28371725). CYP2D6*1 was presumed when testing for the above named variant alleles was negative. Genotyping was performed with the ABI PRISM Ò 7000 SDS instrument in conjunction with the TaqMan Ò Genotyping Master Mix using pre-developed TaqMan Ò Drug Metabolism Genotyping Assays (Applied Biosystems, Foster City, California, USA) for rs16947, rs1135840, rs35742686, rs3892097, rs5030655, rs1065852, rs28371706, rs59421388, and rs28371725. Data were analyzed with the ABI Prism 7000 SDS 1.2.3 Software (Perkin-Elmer, Applied Biosystems Division). The samples of peripheral blood were additionally analyzed regarding the CYP2D6*3, *4, *5, *6, *10 alleles, and CYP2D6 gene duplications or multiplications via polymerase chain reaction with subsequent restriction fragment length polymorphism genotyping assays (PCR-RFLP). Details of the genotyping methods are given in Table 1 of the supplemental material.
CYP2D6 phenotype
Based on the CYP2D6 genotype patients were classified into three phenotype groups according to Heller et al. [43] . Patients with one functional allele are defined as EMs (EM/EM, EM/IM, and EM/PM). IMs are homozygous for decreased alleles (IM/IM) or heterozygous for the allelic combination IM/PM. Two nonfunctional alleles define the PM phenotype (PM/PM). In all further analyses we compared EMs with the combined group of IMs and PMs (IM ? PM) using the above definitions; i.e., (EM/EM, EM/IM, and EM/PM) versus (IM/IM, IM/PM, and PM/PM).
Statistical analysis
All categorical data were described using numbers and percentages. Quantitative data were presented using median and range. Survival distributions and median survival times from first relapse were estimated using the KaplanMeier product-limit method, and were compared using the generalized Wilcoxon test including the number of patients, the number of events, median survival, and a 95 % confidence interval (CI). When no information was available, status was coded as missing data. Statistical comparisons were carried out using v 2 test or Fisher's exact test for categorical data and the log-rank test for censored data. p values of \0.05 were considered significant. The Cox proportional hazards model was used to estimate the hazard ratio and confidence intervals, and to adjust for differing risk factor distributions between groups. The proportional hazards assumption was assessed by including the product of the individual terms with time in the models. Statistical analysis was performed using SPSS version 20.0 (SPSS Inc., Chicago, Illinois, USA), resp. R-2.15 for Windows. Deviation of observed genotypes from HardyWeinberg equilibrium was tested using Haploview 4.2 [44] .
Results
We identified 94 ABC patients treated with Tam. The genotype of six samples remained undetermined, thus 88 out of 94 patients were included in our analysis. The baseline characteristics are outlined in Table 1 . The genotype, allelic frequencies, and the predicted phenotype of CYP2D6 are summarized in Table 2 . The observed frequencies did not deviate from those predicted by the Hardy-Weinberg equilibrium and were similar to those previously observed in Caucasians [11] . According to the phenotype definition, 1.1 % of the patients are classified as UMs, 84.1 % as EMs, 3.4 % as IMs, and 11.4 % as PMs (Table 2) .
Patients lacking a fully functional allele (IM ? PM) had a significant shorter PFS compared to patients with at least one functional allele (EM) (PFS: p = 0.017; HR = 2.19; 95 % CI 1.15-4.18; Fig. 1 ). This result is also valid after adjusting by metastatic sites, number of metastatic sites, age, and adjuvant hormonal therapy (PFS: p = 0.023; HR = 2.14; 95 % CI 1.11-4.13).
The median PFS was 9 months (95 % CI 4.6-13.4) for the IM ? PM-group, and 14 months (95 % CI 10.7-17.3) for the EM-group. OS was significantly shorter for patients with nonfunctional or reduced-function alleles (IM ? PM) compared to the EM-group (OS: p = 0.028; HR = 2.79; 95 % CI 1.12-6.99; Fig. 2 ). The OS rate at 5 years was 76.3 % (95 % CI 64.5 % -88.0 %) for the EM-group and 45.8 % (95 % CI 11.5 % -80.2 %) for the IM ? PM-group. OS stratified by phenotypes of CYP2D6 and adjusted by metastatic sites, the number of metastatic sites, age and adjuvant hormonal therapy slightly decreased from 2.79 to 2.50 with borderline significance (OS: p = 0.054; HR = 2.50; 95 % CI 0.99-6.31).
The percentage of CB, i.e., patients with objective response (=complete response or partial response or stable disease for at least 6 months), was 73 % for EM and 38.5 % for the IM ? PM-group (p = 0.019; Fig. 3 ). The median duration of CB was 15 months for EM and 11 months for the IM ? PM-group. There was no significant difference in OS for patients with clinical benefit stratified by the above 2 phenotype groups (OS: p = 0.547; HR = 1.58; 95 % CI 0.35-7.09).
Furthermore, we found that 46.2 % of the patients with an IM or PM phenotype had a disease progression in comparison with 16 % of the EM (Pearson v 2 p = 0.013).
Discussion
In the present study, we show that hormone receptor positive ABC patients with at least one functional CYP2D6-allele exhibit a significantly longer PFS and OS compared to patients with a PM or IM-predicted phenotype when receiving Tam. The influence of CYP2D6 on efficacy of palliative Tam treatment is also reflected in the observed higher percentage of CB in the EM-predicted phenotype group. To the best of our knowledge, only two other studies have been published so far which examine the relationship between CYP2D6 and Tam treatment in the palliative setting [14, 15] . In the first published study on ABC patients, Lim et al. [14] reported on an influence between the CYP2D6 genotype and time to progression (TTP) in Tam-treated Asian individuals. Homozygous carriers of CYP2D6*10/*10, a major genotype in Asians, demonstrated a significantly shorter TTP than carriers of at least one functional allele. The major limitation of this study, however, is the small number of only 21 ABC patients.
Lammers et al. [15] analyzed a population similar in size to ours (n = 99). In contrast to our findings, OS was only significantly shorter in the PM phenotype group compared to EM, whereas, EMs and IMs showed comparable results regarding TTP and OS. This difference might be explained by the differing genotype-based phenotype classifications used. Furthermore, patients in the above named study were treated with an unusual high dose of 40 mg Tam per day, compared to 20 mg per day which is the standard regimen in Germany in both the adjuvant as well as in the palliative setting. It was shown recently that doubling the Tam dose can increase endoxifen concentrations in IM to levels comparable to EM [45] . Thus, the comparable results regarding TTP and OS between IM and EM in the study by Lammers et al. might be a result of sufficient plasma endoxifen level in the IM group due to the higher Tam dose. Prospective studies that test the relationship between dose escalation and CYP2D6 status are ongoing (for example: NCT01192308; NCT01075802).
In contrast to the studies in the palliative setting, the results in the adjuvant and preventive settings are highly inconsistent.
The reasons for these contradictory results are controversially discussed [46] [47] [48] [49] [50] [51] [52] . In this context, attention should be drawn to the methodological differences of the studies. One example is the use of different DNA sources between the studies (blood vs. FFPE tissue, normal tissue vs. tumor tissue). Generally, genotyping of CYP2D6 variants in FFPE tissue is challenging, as these samples are often degraded [53] . The extent of fragmentation can vary greatly between extensively degraded DNA (\100 base pairs) and relatively intact DNA [53] , therefore a distinction between the known CYP2D6 pseudogenes and CYP2D6 might often fail. Additionally, the FFPE processing of these DNA samples often results in chemical modification and contaminations that can inhibit downstream molecular reactions [53] . In our genetic tissue analysis, CYP2D6*4 was the only allele that we was reliably detected in FFPE tissue by real-time PCR. Determination of CYP2D6*3, *5, *6, *10, *17, *29, and *41 was-in our hands-not specific and reliable enough to be included in the genotype analysis. The reasons for this were, on the one hand a weak signal intensity of the allelic discrimination by real-time PCR despite preamplification of CYP2D6 described by Baak-Pablo et al. [54] , and on the other hand genotype differences between preamplificated samples and their controls. Therefore, we excluded these results from our statistical analyses. We presume that similar difficulties might have occurred in other studies as well. Several studies, particularly the genotyping analyses of the ATAC and BIG 1-98 populations [31, 32] , used tumor tissue for their genetic investigations. However, tumor DNA exhibits significant differences from germline DNA. For example, a frequent ''loss of heterozygosity'' has been reported, especially on chromosome 22q13, where the CYP2D6 gene is located [55] . This is one of the reasons why the genotyping results of the studies mentioned above have been questioned before [48] . To eliminate such a potential single point of failure, we only used DNA from histological verified tumor-free tissue.
In addition, there is a large heterogeneity between the studies in analyzed alleles and the CYP2D6 phenotype classification. Though most of the studies have detected the CYP2D6*4 allele, only about half of them have determined the most common intermediate alleles CYP2D6*10 and CYP2D6*41. Although there is a consensus on the classification of carriers of two non-functional alleles as PM, the definition of the other predicted CYP2D6 phenotypes is less consistent and was differently used in the analyses published so far [15, 16, 19, 21, 31, 32, 56, 57] .
Besides these methodological reasons, differences in the study populations, for example the inclusion of patients with negative or unknown receptor status, might contribute to the divergent results [51] . Moreover, comedication and the use of CYP2D6 inhibitors have been considered only in some studies [15, 32] , even though the simultaneous use of CYP2D6 inhibitors reduce the efficacy of Tam treatment [15] . To exclude this confounding factor, we only included patients without CYP2D6 inhibitor comedication.
In our opinion the clinical significance of CYP2D6 on the efficacy of Tam treatment is as yet not sufficiently understood. The setting of palliative Tam treatment might be more appropriate to explore the influence of CYP2D6, because due to a more direct effect on the tumor in the advanced setting treatment effects can be more easily measured and outcome parameters are less influenced by potential unknown confounding factors.
Although prospective trials are needed to further define the role of CYP2D6 in ABC patients, our results together with the previously published reports [14, 15] 
